RTX between the responder and the 7 nonresponder patients. Conclusions: Only a minority (1 of 8) in our series of adult patients with FSGS showed positive effects of high doses of RTX. Future studies are warranted to investigate more promising therapeutic options in the management of FSGS.
High

Introduction
Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome in children and in adults. More than 60% of patients treated with steroids achieve remission [1] . However, among those achieving remission (either complete or partial), approximately half of them experience relapses [2] . In patients with frequent relapses or steroid dependency, comorbidities secondary to steroid treatment may be challenging and deeply impacting in terms of prognosis and quality of life [3] . Longterm complications of steroid regimens, such as impaired Keywords Rituximab · Focal segmental glomerulosclerosis · Idiopathic focal segmental glomerulosclerosis Abstract Background: A beneficial effect of rituximab (RTX) on focal segmental glomerulosclerosis (FSGS) in pediatric patients or in transplant recipients has been reported in isolated cases. However, the use of RTX in adult patients with idiopathic FSGS needs further investigation. Methods: Eight patients who had biopsy-proven FSGS (63.9 ± 14.0, range 40-81 years, 4 women, 4 men) with major risk factors precluding corticosteroids or conventional immunosuppression were treated with a high dose of RTX (8 weekly doses of 375 mg/m 2 ) and prospectively followed up for at least 2 years (29.1 ± 8.8 months, range 24-42 months). Results: RTX failed to improve proteinuria in 7 out of 8 patients, who had persistent nephrotic proteinuria. In one case, a rapidly deteriorating renal function was also observed. Only one patient showed an improvement in renal function and a remarkable reduction in proteinuria. There were no differences in clinical or laboratory characteristics or in the CD20 B lymphocyte count after glucose tolerance, hypertension, osteopenia/osteoporosis, dyslipidemia, and an increased risk of infections and cardiovascular events are common. Steroid-sparing agents such as cyclosporine A, mycophenolate mofetil, azathioprine, tacrolimus, levamisole, cyclophosphamide, and chlorambucil have been investigated in FSGS as second-and third-line treatment [4] [5] [6] [7] [8] , but adverse events and toxicities attributed to these immunosuppressants also limit their long-term use.
Rituximab (RTX) is a chimeric monoclonal antibody directed against CD20-positive B-cells and is a part of the therapeutic option in diseases like rheumatoid arthritis [9] and ANCA-associated vasculitis [10] . Moreover, RTX is a valuable option in the treatment of several connective tissue diseases [11] [12] [13] and immune-meditated glomerular diseases such as idiopathic membranous nephropathy [14, 15] and Henoch-Schonlein purpura nephritis [16] . RTX has emerged as an alternative treatment of frequently relapsing, steroid-dependent or steroid-resistant nephrotic syndrome in children [17] [18] [19] [20] . A beneficial effect of RTX on FSGS in pediatric patients or in transplant recipients has been shown in isolated reports and in a few case series [21] [22] [23] . However, in adult patients with FSGS with persisting nephrotic syndrome, data on the efficacy of RTX treatment are still elusive [24, 25] .
Methods
Consecutive patients meeting the following criteria were prospectively enrolled in our study: (1) biopsy-proven FSGS; (2) nephrotic syndrome; (3) absence of concomitant infections, comorbid conditions, or systemic diseases that could have a pathogenic relationship with the nephrotic syndrome; and (4) presence of major risk factors precluding the use of corticosteroids. For each patient, the following data were extracted from patient records: demographic characteristics, clinical data (elevated blood pressure [BP] , body weight, edema), and time elapsed since the diagnosis of FSGS by renal biopsy. Any nonspecific antiproteinuric treatment before RTX administration was also recorded. A careful analysis of familial history of renal diseases was performed in every case. The pathologic variant of FSGS (collapsing, tip lesion, cellular variant, perihilar, and FSGS not otherwise specified) was recorded, as well as the percentage of glomeruli showing a global sclerosis. The severity of tubulointerstitial fibrosis was graded as absent (0), mild (+), moderate (++), and severe (+++).
For all patients, the following clinical and laboratory parameters were recorded at baseline (onset of RTX administration), monthly during the treatment period, and then every 3-6 months after treatment: BP, body weight, complete blood counts, electrolytes, and routine serum biochemistry profile (including total proteins, albumin, a lipid panel, and serum creatinine [sCr]). Creatinine clearance and proteinuria were measured using 24-h urine collections at each time point. For all patients, B-cell flowcytometry was performed after every RTX treatment. For comparison of variables at baseline and follow-up, Student t test was used for normally distributed parameters, and the nonparametric Mann-Whitney test for non-normally distributed parameters. Correlations were calculated and significance determined by Fisher's test. For these analyses, with SPSS (IBM Corporation, NY, USA) software programs was used. p < 0.05 was considered significant.
RTX Protocol
RTX was given at high dose in 8 weekly infusions of 375 mg/m 2 . This scheme was chosen when analyzing available literature about the use of RTX in adult patients with FSGF. In their report, Fernandez-Fresnedo et al. [24] showed that only 3 out of 8 patients who had a positive response to RTX had received more RTX doses (e.g., 8 infusions of 375 mg/m 2 ) than the other 5 patients, in whom 4 weekly intravenous infusions of 375 mg/m 2 of RTX were administered.
Results
Eight adult patients who had biopsy-proven primary FSGS received a high dose of RTX (8 weekly doses of 375 mg/m 2 ) and were prospectively enrolled in our study. The main demographic and clinical characteristics of the patients are summarized in Table 1 . Patients were 4 women and 4 men, with a mean age of 63.9 ± 14.0 (range 40-81 years) and a mean disease duration of 3 ± 3 months (range 1-6 months). All patients had major risk factors precluding corticosteroid regimens; in detail, all the patients had elevated BP, 4 were diabetic (patients #1, 4, 6, 7), 3 were older than 70 years (patients #3, 6, 7), and 3 had osteopenia (patients #3, 6, 7).
All patients had marked proteinuria at the time of RTX treatment (mean proteinuria 5.3 ± 1.9 g/24 h; range 3.6-8.0 g/24 h), and their mean sCr was 2.6 ± 1.2 mg/dL (range 0.9-3.7 mg/dL). Supportive treatments of nephrotic syndrome (including diuretics, statins, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers) given at the time of RTX administration were maintained during follow-up.
The characteristic features of renal biopsies are specified in Table 2 . The percentage of globally sclerosed glomeruli ranged from 10 to 40%. Interstitial fibrosis was absent in 2 cases, mild in 4, and moderate in 2. No correlation between histologic features and response to RTX treatment was found.
The tolerance to RTX infusion was good, and no adverse effects were observed during the period of RTX administration or during the follow-up. The mean duration of follow-up after RTX therapy was 29.1 ± 8.8 months (range 24-42 months).
As shown in Figure 1 , RTX failed to resolve nephrotic syndrome in most of the patients. Patients #1, 4, and 5 persisted with a massive proteinuria and a roughly stable high sCr. Patient #5 showed a clear worsening of renal function accompanied by a persistent massive proteinuria. Patients #6 and #7, who had clearly impaired renal function at baseline (sCr 2.8 and 3.5 mg/dL), showed a marginal nonsignificant proteinuria decrease after the RTX course. Patient #8 presented with conserved renal function and her proteinura remained stable after 24th of follow-up.
Only one patient (patient #3) experienced sustained improvement. She presented with severe proteinuria and deteriorated renal function at the time of RTX administration (proteinuria 7 g/24 h and sCr 3.7 mg/dL, respectively) and showed a clear proteinuria decrease in non-nephrotic values (1.5 g/24 h) accompanied by a slight improvement of the renal function ( Table 1 ) .
In the whole group of patients, we failed to observe a significant decrease in proteinuria levels (5.3 ± 1.9 g/24 h at baseline to 3.9 ± 1.8 g/24 h at the end of follow-up, and sCr increased from 2.6 ± 1.2 to 3.5 ± 2.5 mg/dL (ns). CD20+ B lymphocytes decreased to undetectable levels after the first course of RTX in all the patients. Time to recover a normal CD20+ count after RTX treatment ranged between 9 and 25 months (12.5 ± 5.6 months) as shown in Figure 2 . No differences in the CD20+ B lymphocyte profile were observed in the patient with a positive response to RTX treatment (patient #3). FSGS, focal segmental glomerulosclerosis; RTX, rituximab; ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blocker; sCr, serum creatinine (mg/dL); prot., proteinuria (g/24 h); BP, blood pressure, mm Hg; alb., serum albumin, g/L. 
Discussion
Some case reports and observational studies have created a considerable expectation about the therapeutic possibilities of RTX in nephrotic syndrome [17, 18] . Uncontrolled studies have shown a significant decrease in proteinuria after RTX treatment in patients with idiopathic membranous nephropathy [14, 26] . Conversely, several case reports in pediatric patients on in transplant suggested that RTX could be a potentially effective and safe alternative in FSGS [27] [28] [29] .
The possibility of a beneficial effect of RTX on primary FSGS was initially suggested by the publication of information on patients who had recurrent FSGS in renal grafts and had remission of nephrotic syndrome after treatment with RTX. To date, a very limited number of adult patients with FSGS has been successfully treated with RTX [30] [31] [32] [33] [34] . Some of these patients were treated with RTX because of the development of lymphoproliferative disorders [30, 32] , suggesting a possible pathogenic relationship between such hematologic disorder and the pathogenesis of proteinuria. Conversely, 2 other reports, including 6 patients (4 adults, 2 children) showed a failure of RTX to improve nephrotic syndrome in renal transplant patients with recurrent FSGS [35, 36] .
To date, 6 reports including 10 children or adolescents with primary FSGS in their native kidneys were treated with RTX [27-29, 37, 38] . All of them had a positive response, achieving complete or partial remission of nephrotic syndrome, although in some cases, RTX was administered when proteinuria was defined by non-nephrotic values.
Fernandez-Fresnedo et al. [24] in their study showed poor efficacy of RTX in adult patients with severe nephrotic syndrome. In their cohort, 5 out of 8 patients continued to show massive nephrotic proteinuria, and renal function exhibited a rapid deterioration in follow-up in 2 of them; however, 2 other patients, who had a very poor renal prognosis (massive proteinuria accompanied by increasing sCr), showed a partial improvement of renal function accompanied by a remarkable reduction in proteinuria [24] . The remaining patient, who received 2 RTX courses, showed a clear proteinuria reduction after every RTX treatment, but this beneficial effect was only transitory [24] .
In our cohort, which is one of largest of adult patients with the longest follow-up ever reported, no significant 112 decrease in proteinuria levels paralleled with a substantial increase in sCr was observed. Only one patient had a reduction of about 80% of baseline value of proteinuria.
The reasons why RTX seems to be effective in pediatric patients with primary FSGS or in transplant recipients but fails to induce any improvement in adult patients with idiopathic FSGF remain unknown. The present cohort had some peculiarities. First, our patients sample included adult cases with definite contraindication to corticosteroids and recent onset of disease. Second, RTX was used as a first-line treatment on naïve patients. Third, our patients received very high doses of RTX and the CD20+ B cells profile excluded any possibilities of hematologic resistance or developing of neutralizing anti-chimeric antibodies. This study including one of the largest cohort of adults patients with idiopathic FSGS with the longest follow-up showed that despite the administration of the high dose of RTX no definite benefit in terms of proteinuria or renal function could be observed, and definitely raised the question of ethical justification of treating patients with adult onset FSGS with RTX.
Conversely, our study does have some limitations. In the context of a real-world scenario, the presence of several co-morbidities precluding the use of corticosteroids (e.g., diabetes, high BP) might have resulted in the substantial heterogeneity in biopsy findings at electronic microscopy. A beneficial role of RTX in a restricted cohort homogeneous for widespread foot process effacement at electronic microscopy cannot be ruled out.
Conclusions
Our results do not support the promising effects initially reported with RTX in adults with FSGS. Among 8 adult patients who had nephrotic proteinuria, only one patient showed a sustained positive response, with a reduction of 80% of baseline of proteinuria value. More studies are necessary to further characterize the FSGS patients who could benefit from RTX.
